Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schippinger, W; Dandachi, N; Regitnig, P; Hofmann, G; Balic, M; Neumann, R; Samonigg, H; Bauernhofer, T.
The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
Am J Clin Pathol. 2007; 128(4):630-637
Doi: 10.1309/51KPD70348RP6XTE
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Schippinger Walter
- Co-Autor*innen der Med Uni Graz
- Balic Marija
- Bauernhofer Thomas
- Dandachi Nadia
- Hofmann Guenter
- Regitnig Peter
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We investigated the predictive value of HER-2/neu and epidermal growth factor receptor (EGFR) in tumor tissue and prechemotherapy serum for histopathologic response in 108 patients with breast cancer undergoing neoadjuvant anthracycline-based chemotherapy. Response to chemotherapy, assessed by histopathologic classification of regression (grade 0 [no therapy effect] to 4 [no residual tumor]), correlated significantly with prechemotherapy serum HER-2/neu levels. Median prechemotherapy serum HER-2/neu levels were significantly higher in patients with regression grades 1 through 4 compared with those in patients with regression grade 0 (9.6 vs 8.55 ng/mL; P = .011; 95% confidence interval [CI], .009-.014). Median pretreatment serum HER-2/neu levels of patients with complete pathologic response (pCR) were significantly higher than in patients with moderate or no treatment response (10.95 vs 9.1 ng/mL; P = .041; 95% CI, .036-.046). Receiver operating characteristic curve analysis revealed a serum HER-2/neu value of more than 10.3 ng/mL to predict a pCR with 80% sensitivity and 69.4% specificity. There was no significant correlation of response with HER-2/neu and EGFR scores in tumor tissue or with serum EGFR levels. Results demonstrate prechemotherapy serum HER-2/neu to be a significant predictor of response to neoadjuvant anthracycline-based chemotherapy for breast cancer.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Anthracyclines - therapeutic use
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology
- Female -
- Humans -
- Middle Aged -
- Neoadjuvant Therapy -
- ROC Curve -
- Receptor, Epidermal Growth Factor - metabolism
- Receptor, erbB-2 - metabolism
- Treatment Outcome -
- Tumor Markers, Biological - metabolism
- Find related publications in this database (Keywords)
- breast cancer
- epidermal growth factor receptor
- EGFR
- HER-2/neu
- predictive parameters